We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Isolation of Pure Form of Coronavirus Nucleoprotein to Help Create More Accurate COVID-19 Antibody Tests

By LabMedica International staff writers
Posted on 09 Feb 2022
Print article
Illustration
Illustration

Biologists have isolated the coronavirus nucleoprotein in its pure form to improve the accuracy and sensitivity of COVID-19 antibody tests.

Scientists from Research Center of Biotechnology RAS (Moscow, Russian Federation) have demonstrated that at least two different methods of directed RNA removal are required for obtaining SARS-CoV-2 nucleoprotein, completely free from any RNA admixtures. Such preparation helps to determine the presence of antibodies to SARS-CoV-2 with significantly higher sensitivity.

The SARS-CoV-2 nucleoprotein is the main protein in viral particles. It folds the RNA of the virus into a compact structure. This is needed to transfer the hereditary material to the "next generations" of virions (viral particles) before they are separated from the infected cell. COVID-19 patients usually develop antibodies (immunity proteins that are specifically connected to a specific fragment of the "enemy" protein) to the SARS-CoV-2 nucleoprotein, even if the infection was asymptomatic.

But people inoculated with mRNA vaccines and adenovirus vaccines such as Sputnik V or ChAdOx1 (AstraZeneca) do not develop antibodies to the nucleoprotein. The reason is that these vaccines do not code nucleoprotein, but rather S-protein, "spikes" that allow the virus to attach to the human cell and infect it. The immunity of people who had contracted the virus, unlike vaccinated people, encounters all the proteins of the virus and develops all forms of antibodies to nucleoprotein too.

To create more accurate antibody tests, it is necessary to isolate the pure form of protein to which the antibodies are specific. The test works because the protein finds "its" antibody and binds to it. In the case of a nucleoprotein, however, there are many obstacles for binding of antibodies. Part of the protein's surface is closed by bound RNA, and another part is inaccessible because nucleoproteins form huge supramolecular structures. Since the nucleoprotein "in the line of duty" binds to RNA, separating one from the other is a complicated process.

"With nucleoprotein antibody tests, it is possible to know exactly whether a vaccinated person has been infected with SARS-CoV-2. Tests for antibodies to the S-protein do not provide this clear information," said Ivan I. Vorobiev, Doctor of Biological Sciences, one of the authors of the study and Head of the laboratory of Mammals Cells Bioengineering of the Research Center of Biotechnology RAS. "Apparently, the omicron variant can easily infect vaccinated persons, but it rarely re-infects those who have already been infected and very rarely infects those who have been infected and vaccinated afterward. There are also commercial tests for antibodies to the SARS-CoV-2 virus nucleoprotein. Unfortunately, some of them give plenty of false positives, while others, with low sensitivity, give many false negatives."

Related Links:
Research Center of Biotechnology RAS
 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.